Professional Twitter land: health policy/economics, HTA, data stuff, cancer, pharmacoepi, pharmacy & HSR, and the occasional pun. Member of @YoungGasteiners.
Great opportunity to make your voice heard. Survey link here https://t.co/rtihSwZFmr
Survey open until 30th June 2023!
#Raredisease @NI_RDP @NIPHRN@a_j_mcknight@sujas15
Please Share
Assessing the value of new cancer treatments & innovations is the theme of the 2nd HORC webinar in the Future of Cancer in Ireland series taking place on 18 May.
Speakers: @CrooksGeorge, @AvrilKennan, @Susan_Spillane
Moderator: @ronan_glynn
Register: https://t.co/9UncOWrihW
We published a health technology assessment (HTA) on the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme (NNBSP). You can find out more here: https://t.co/G7JGfMIfWt
@SPHeREprogramme congrats SPHeRE scholar Kathleen Harkin on winning the student oral presentation award at #HTAi2022Utrecht! A really thought-provoking discussion of what we mean by 'life cycle' evaluation of medical devices, and why important. 🇮🇪
Absolutely delighted to have been shortlisted in 3 categories in last night's @RAMIreland research awards, and was shocked to have won 2 of them (Public Health Medicine/Epidemiology and Psychiatry).
Thank you @RAMIreland for a brilliant night!
@dannifromdublin@amelia_epi We were so confused about why a bunch of roads were closed when heading in. So much for pleasant Saturday walk about the city! Definitely checking Twitter before we leave the house next time...
@Tasmin1974 @petermbarrett1 I think it's also relevant that in countries such as the UK, the role of public health consultant is inclusive of specialists who do not have an undergraduate in medicine. This is not the case in Ireland - there is no route except through bachelors. Surely important re supply?
Several interesting pharmacoeconomic / HTA articles on cancer drugs published yesterday in @JAMAInternalMed. + associated commentary: https://t.co/whC3cIFB5y
Great #SPHeRE presentation from @KieranWalshMPSI on our study of duration of infectiousness of #SARSCoV2#COVID19. Will be important to monitor whether any emerging difference in infectiousness duration associated with new variants of concern.
@jamesfomahony @Varletron Any chance you could share by DM, James? I've been noticing recently how there seems to be a real perception with screening that low obvious direct cost = cost effective (and therefore 'should be implemented') so I'm interested in papers that might be contributing to this.